Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop (2024)

Chapter: Appendix A: Workshop Agenda

Visit NAP.edu/10766 to get more information about this book, to buy it in print, or to download it as a free PDF.
Previous Chapter: References
Page 115 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel

Appendix A

Workshop Agenda

ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER:
DIAGNOSIS, TREATMENT, AND IMPLICATIONS FOR DRUG DEVELOPMENT—A WORKSHOP

Keck Center, 500 Fifth St. NW
Washington DC, 20001

DAY 1: TUESDAY, DECEMBER 12, 2023

9:00 am WELCOME, OPENING REMARKS, AND SETTING THE STAGE
CRAIG B.H. SURMAN, Workshop Co-chair

Director, Clinical and Research Program in Adult ADHD

Massachusetts General Hospital

Associate Professor of Psychiatry

Harvard Medical School
9:35 am REGULATORY OVERVIEW
MARTA SOKOLOWSKA

Deputy Center Director

Substance Use and Behavioral Health

Center for Drug Evaluation and Research

U.S. Food and Drug Administration
Page 116 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel

SESSION I—DIAGNOSIS OF ADULTS WITH ADHD

Session Objectives:

  • Discuss the criteria and available tools for diagnosis of ADHD in adults (including DSM-5 criteria, assessment tools, best practices in diagnosing the condition);
  • Explore gaps and barriers when it comes to appropriate diagnosis of ADHD for different adult populations; and
  • Consider the long-term public health implications of under-diagnosing, differential diagnosing, and misdiagnosing ADHD in adults and considerations for different populations.
9:55 am Presentation
ANN CHILDRESS

President

Center for Psychiatry and Behavioral Medicine, Inc.

President

The American Professional Society for ADHD and Related Disorders
10:20 am Panel Discussion
Moderator: Steve Lee, University of California, Los Angeles
Clinical Diagnosis Perspective

NAPOLEON HIGGINS

President and Chief Executive Officer

Bay Pointe Behavioral Health
Clinical Screening Perspective

SARA L. WEISENBACH

Associate Professor of Psychology in Psychiatry, Harvard Medical School

President, American Psychological Association, Society for Clinical Neuropsychology (Division 40)

Chief of Neuropsychology

McLean Hospital
Lived Experience Perspective

TAMARA ROSIER

Owner, ADHD Center of West Michigan

President ADHD Coaches Organization
Page 117 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Research Perspective

MARGARET SIBLEY

Professor of Psychiatry and Behavioral Sciences

University of Washington School of Medicine
Discussion Questions:
  1. Why do clinicians find it challenging to diagnose ADHD in adults (e.g., co-morbidities, differential diagnosis with other conditions such as depression, anxiety, other psychiatric conditions, and/or COVID-19)?
  2. What barriers do adults experience when seeking a diagnosis of ADHD, particularly those from minority and medically underserved communities?
  3. How does an ADHD diagnosis, or the lack of one, impact individuals across adulthood?
  4. How is ADHD diagnosed under the DSM 5 criteria?
11:20 am Coffee Break

SESSION II—MEDICATION OPTIONS FOR ADULTS WITH ADHD: RISKS AND BENEFITS

Session Objectives:

  • Consider what is known and unknown about the risks and benefits of ADHD medication use in adult populations;
  • Consider the public health implications for potential overprescribing of Schedule II stimulants;
  • Discuss the barriers (e.g., legal, regulatory, social, cultural) to access of equitable treatment for adults with ADHD; and
  • Explore approaches for alternative treatment options for adults with ADHD (e.g., non-pharmacological interventions, re-tooling of existing medications, new drug development) that may reduce the risk of harm to patients, that take into account social and cultural considerations.
11:50 am Presentation
DAVID W. GOODMAN

Assistant Professor of Psychiatry and Behavioral Sciences

Johns Hopkins University School of Medicine
Page 118 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
12:10 pm Panel Discussion
Moderator: James (Jimmy) Leonard, Maryland Poison Center; University of Maryland School of Pharmacy
Lived Experience Perspective

DUANE GORDON

President

Attention Deficit Disorder Association
Clinical/Pharmacology Perspective (Medication Treatments)

ANGELA MAHOME

Staff Psychiatrist

The University of Chicago
Research/Clinical Perspective (Nonmedication Treatments/CBT)

J. RUSSELL RAMSAY

Independent Practice

Former Co-Founder, Co-Director, Adult ADHD Treatment and Research Program

University of Pennsylvania
Regulatory Perspective

TIFFANY R. FARCHIONE

Director, Division of Psychiatry

Center for Drug Evaluation and Research, FDA
Discussion Questions:
  1. What is known and unknown about the risks and benefits of medication (stimulant and non-stimulant) use for the treatment of ADHD in adult populations?
  2. What are the primary barriers (e.g., legal, regulatory, social, cultural) to appropriate treatment for adults with ADHD and how have these barriers been overcome? What are the health equity implications of these approaches?
  3. How can prescribers, clinicians, and other providers be better informed regarding the treatment options available to their patients?
1:10 pm Lunch Break
Page 119 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel

SESSION III—IMPLICATIONS FOR DRUG DEVELOPMENT

Session Objectives:

  • Consider areas of unmet treatment needs for adults with ADHD that could potentially be addressed through new and/or improved therapeutics; and
  • Explore challenges and opportunities for the development of new and improved therapeutics for the treatment of ADHD, including options that may reduce the risk of diversion.
2:00 pm Presentation
CRAIG BERRIDGE

The Patricia Goldman-Rakic Professor of Psychology

University of Wisconsin, Madison
2:20 pm Panel Discussion
Moderator: Stevin Zorn, MindImmune Therapeutics, Inc.
Industry Perspective

JONATHAN RUBIN

Chief Medical Officer and Senior Vice President of Research & Development

Supernus Pharmaceuticals
Neurobiology/Pharmacology Perspective

AMY ARNSTEN

Albert E. Kent Professor of Neuroscience and Professor of Psychology

Yale School of Medicine
Regulatory Perspective

ERIKA LIETZAN

William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law

University of Missouri School of Law
Discussion Questions:
  1. How do available therapeutic treatment options meet the needs of adults with ADHD? What are the gaps/unmet medical needs?
Page 120 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
  1. How might alternative treatment options for adults with ADHD reduce the risk of harms, such as misuse potential, overdose, and toxicity?
  2. What are the barriers and opportunities to the development of new medications for treating adults with ADHD?
3:20 pm Coffee Break

SESSION IV—DAY 1 SYNTHESIS AND DISCUSSION

Session Objectives:

  • Discuss key themes from previous workshop sessions;
  • Lay out questions to be addressed; and
  • Consider next step opportunities for improving the diagnosis and treatment of adults with ADHD; implications for drug development.
3:50 pm Panel Discussion
Moderator: Craig B. H. Surman, Massachusetts General Hospital; Harvard Medical School
Pharmacology Perspective

ALMUT WINTERSTEIN

Director, Center for Drug Evaluation and Safety (CoDES) and Consortium for Medical Marijuana Clinical Outcomes Research

Distinguished Professor, Pharmaceutical Outcomes and Policy

University of Florida
Industry Perspective

DAVID BAKER

Former Pharmaceutical Executive – Shire, Alcobra, Vallon Pharmaceuticals

Board Member

Edge Foundation
Lived Experience Perspective

KOFI OBENG

Executive Director

Attention Deficit Disorder Association
Page 121 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Resources and Education Perspective

SUNNY PATEL

Senior Advisor for Children, Youth and Families

SAMHSA
Research Perspective

MARY SOLANTO

Professor of Pediatrics and Psychiatry

Zucker School of Medicine at Hofstra-Northwell
Discussion Questions:
  1. Based on the day’s sessions, what are the main themes you heard regarding the diagnosis, treatment, and drug development for ADHD in adult populations? What questions remain?
  2. How can the use of a health equity framework help the those with adult ADHD, health professionals, and others better understand the social, political, economic, and environmental factors impacting the diagnosis and treatment of adult ADHD?
  3. How do we bridge the gap from where we are now to where we want to be? What is needed and from whom?
  4. What are some key things from today’s sessions we should keep in mind as we move into Day 2?
4:35 pm Audience Q&A
DAY 1 CLOSING REMARKS
CARLOS BLANCO, Workshop Co-chair

Director, Division of Epidemiology, Services, and Prevention Research

National Institute on Drug Abuse, NIH
5:00 pm Adjourn Workshop Day 1
5:00 pm Reception
Page 122 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel

DAY 2: WEDNESDAY, DECEMBER 13, 2023

8:30 am OPENING REMARKS
CARLOS BLANCO, Workshop Co-chair

Director, Division of Epidemiology, Services, and Prevention Research

National Institute on Drug Abuse, NIH
8:40 am FIRESIDE CHAT
CARLOS BLANCO, Workshop Co-chair

Director, Division of Epidemiology, Services, and Prevention Research

National Institute on Drug Abuse, NIH
EVELYN POLK GREEN

Immediate Past President;

Attention Deficit Disorder Association

Past President;

Children & Adults with Attention Deficit/Hyperactivity Disorder

SESSION V—ENABLING ACCESS TO RESOURCES AND SHARED DECISION MAKING FOR ADULTS WITH ADHD AND THEIR PROVIDERS

Session Objective:

  • Share perspectives and available resources for prescribers, clinicians, and patients on the risks and benefits of ADHD medication use in adults, particularly for underserved populations;
  • Discuss practical approaches that have helped overcome barriers (e.g., stigma, misdiagnosis) to appropriate diagnosis and treatment of adults with ADHD; and
  • Consider opportunities to enable shared decision making between patients and their providers regarding the diagnosis and treatment of ADHD.
9:20 am Presentation
MARK OLFSON

Professor of Psychiatry, Medicine, and Law;

Professor of Epidemiology

Columbia University
Page 123 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
9:40 am Presentation
LARA ROBINSON

Behavioral Scientist

National Center on Birth Defects and Developmental Disabilities, CDC
9:55 am Panel Discussion
Moderator: Andrea Chronis-Tuscano, University of Maryland, Department of Psychology
Lived Experience Perspective
KYLIE BARRON
Clinical Perspective

BRANDI WALKER

Chief Executive Officer

Marie Pauline Consulting, LLC
Psychiatrist Perspective

BENJAMIN CHEYETTE

Psychiatrist

Director of ADHD Programming

Mindful Health Solutions
Telehealth and Social Media Perspective

JESSICA GOLD

Associate Professor, Department of Psychiatry, University of Tennessee Health and Science Center

Chief Wellness Officer

University of Tennessee (UT) System

(As of 2/1/2024)
Discussion Questions:
  1. What methods and/or systems are in place to support prescribers, clinicians, and other providers who diagnose and treat adults with ADHD? What else is needed?
  2. Are there lessons learned from the diagnosis and treatment of pediatric populations that may be applicable for adult populations?
Page 124 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
  1. What approaches have and/or could help support adults with ADHD make informed decisions about the risks and benefits of ADHD medication use?
  2. How can we best disseminate evidence-based educational materials/content about adult ADHD to patients (including those from diverse backgrounds) so that they can engage in informed discussions around their care?

SESSION VI—PUBLIC HEALTH CONSIDERATIONS AND HARM REDUCTION STRATEGIES FOR ADHD MEDICATION USE

Session Objectives:

  • Share perspectives on the causes, perceptions, consequences, and health equity implications of non-medical use of prescription stimulants;
  • Discuss what is known and unknown about the intersection of ADHD medication use (medical and non-medical) and opioid use; and
  • Consider how strategies to reduce the misuse of ADHD medications could impact public health (e.g., limiting patient access to medication, exacerbating existing health inequities).
10:55 am Presentation
BROOKE MOLINA

Professor of Psychiatry, Psychology, Pediatrics, Clinical & Translational Science

University of Pittsburgh
11:15 am Panel Discussion
Moderator: Taleed El-Sabawi, Florida International University
Clinical Perspective

ROBIN WEISS

Private Practice of Psychiatry

Past President

Maryland Psychiatric Society
Lived Experience Perspective
PATRICK KELLY
Page 125 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Research/Community Health Perspective

RYAN MCNEIL

Associate Professor, Director of Harm Reduction Research

Yale School of Medicine
Research/Clinical Perspective

KEVIN ANTSHEL

Professor of Psychology and Associate Department Chair

Syracuse University
Discussion Questions:
  1. What is known and unknown about the intersection of ADHD medication use (medical and non-medical) and opioid use?
  2. What are public health and health equity implications of not appropriately treating adults with ADHD?
  3. What strategies (e.g., public health efforts, regulatory policies) have been deployed to reduce the misuse of ADHD medications and what was the impact on people with ADHD? What was the impact on public health?
12:15 pm Coffee Break

SESSION VII—DAY 2 SYNTHESIS AND DISCUSSION

Session Objectives:

  • Discuss key themes from previous workshop sessions; and
  • Consider next step opportunities for improving the diagnosis and treatment of adults with ADHD.
12:45 pm Panel Discussion
Moderator: Carlos Blanco, National Institute on Drug Abuse, NIH
Clinical Perspective—ADHD in underserved populations

JOSEPH SCHATZ

Director, Psychiatric/Mental Health Nurse Practitioner Track

University of Pennsylvania School of Nursing
Lived Experience Perspective

TALEED EL-SABAWI

Assistant Professor of Law

Florida International University
Page 126 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Pharmacology Perspective

MATTHEW RUDORFER

Chief, Psychopharmacology, Somatic, and Integrated Treatment Research Program

National Institute of Mental Health, NIH
Research Perspective

AMELIA ARRIA

Director, Center on Young Adult Health and Development

Professor, Department of Behavioral and Community Health

University of Maryland School of Public Health
Family Medicine Perspective

LATASHA SELIBY PERKINS

Assistant Professor of Medicine

Georgetown University School of Medicine
Discussion Questions:
  1. Based on the day’s sessions, what are the main themes you heard regarding enabling access to resources, shared decision making, and strategies to reduce the misuse of ADHD medications for adults with ADHD? What questions remain?
  2. How can the use of a health equity framework help those with adult ADHD, health professionals, and others better understand the social, political, economic, and environmental factors impacting the health and overall well-being of adults with ADHD?
  3. Considering everything you’ve heard over the past day and a half, what is important for the FDA to know as it relates to diagnosis, treatment, and drug development for adult ADHD?
1:35 pm Audience Q&A
1:50 pm CLOSING REMARKS
MARTA SOKOLOWSKA

Deputy Center Director

Substance Use and Behavioral Health

Center for Drug Evaluation and Research

U.S. Food and Drug Administration
Page 127 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
CRAIG B.H. SURMAN, Workshop Co-chair

Director, Clinical and Research Program in Adult ADHD

Massachusetts General Hospital

Associate Professor of Psychiatry

Harvard Medical School
2:00 pm Adjourn Day 2
Page 128 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel

This page intentionally left blank.

Page 115 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 115
Page 116 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 116
Page 117 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 117
Page 118 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 118
Page 119 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 119
Page 120 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 120
Page 121 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 121
Page 122 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 122
Page 123 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 123
Page 124 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 124
Page 125 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 125
Page 126 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 126
Page 127 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 127
Page 128 Cite
Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.
Save
Cancel
Page 128
Next Chapter: Appendix B: Biographical Sketches of the Workshop Planning Committee, Speakers, Panelists, and Staff
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.